InVivoMAb anti-mouse CLEC9A (CD370) BE0305-R001mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-mouse CLEC9A (CD370) Monoclonal Antibody has the following reported applications: in vivo CLEC9A blockade, in vivo Ag targeting to CLEC9A+ DCs, Western blot, ELISA, Immunoprecipitation, Immunofluorescence, Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-mouse CLEC9A (CD370)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0305-R001mg
Quantity1 mg
Applicationsin vivo CLEC9A blockade, in vivo Ag targeting to CLEC9A+ DCs, Western blot, ELISA, Immunoprecipitation, Immunofluorescence, Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
TargetCLEC9A
IsotypeIgG1, κ
Clone7H11
HostRat
NCBI Full Gene NameC-type lectin domain containing 9A
NCBI Gene AliasesCD370, DNGR-1, DNGR1, UNQ9341
ClonalityMonoclonal
ImmunogenRBL-2H3 cells expressing mouse CLEC9A fused to an HA epitope
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immunology, Innate Immunity

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunityScience immunologyJune 21, 2019Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D, Oberst A.

(2) Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomasEuropean journal of immunologyJuly 1, 2014Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM.

(3) Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9AEuropean journal of immunologyMay 1, 2010Joffre OP, Sancho D, Zelenay S, Keller AM, Reis e Sousa C.

(4) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectinThe Journal of clinical investigationJune 1, 2008Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C.

Be the First to Write a Review!